Last reviewed · How we verify

Hyperbaric Lidocaine 5%

Universitas Sebelas Maret · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Hyperbaric Lidocaine 5% is a Small molecule drug developed by Universitas Sebelas Maret. It is currently FDA-approved. Also known as: Lidodex.

Hyperbaric Lidocaine 5% is a small molecule that blocks the sodium channel alpha subunit, classified as a blocker. It has been studied in clinical trials for use in anesthesia, including for procedures such as prostate cancer surgery and cystoscopy.

At a glance

Generic nameHyperbaric Lidocaine 5%
Also known asLidodex
SponsorUniversitas Sebelas Maret
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hyperbaric Lidocaine 5%

What is Hyperbaric Lidocaine 5%?

Hyperbaric Lidocaine 5% is a Small molecule drug developed by Universitas Sebelas Maret.

Who makes Hyperbaric Lidocaine 5%?

Hyperbaric Lidocaine 5% is developed and marketed by Universitas Sebelas Maret (see full Universitas Sebelas Maret pipeline at /company/universitas-sebelas-maret).

Is Hyperbaric Lidocaine 5% also known as anything else?

Hyperbaric Lidocaine 5% is also known as Lidodex.

What development phase is Hyperbaric Lidocaine 5% in?

Hyperbaric Lidocaine 5% is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing